case studies April 23
|
Variables |
SAR-CoV-2 infection |
Univariable model |
P-value |
|
|
|
n (%)† |
RR |
95% CI |
|
|
Total |
2,611 (38.1) |
|
|
|
|
Main exposure |
|
|
|
|
|
Asthma |
|
|
|
|
|
No |
2,571 (38.1) |
1.00 |
Reference |
|
|
Yes |
40 (41.7) |
1.09 |
0.86, 1.39 |
0.460 |
|
Covariates |
|
|
|
|
|
Sex |
|
|
|
|
|
Female |
1,253 (38.5) |
1.00 |
Reference |
|
|
Male |
1,358 (37.8) |
0.98 |
0.92, 1.04 |
0.533 |
|
Age (years) |
|
|
|
|
|
< 2 |
360 (28.2) |
1.00 |
Reference |
|
|
2 - < 6 |
612 (38.2) |
1.35 |
1.22, 1.51 |
< 0.001 |
|
6 - < 12 |
1,090 (41.3) |
1.47 |
1.33, 1.62 |
< 0.001 |
|
12 - < 15 |
549 (41.3) |
1.47 |
1.32, 1.64 |
< 0.001 |
|
Nationality |
|
|
|
|
|
Thai |
2,421 (39.1) |
1.00 |
Reference |
|
|
Non-Thai |
190 (28.7) |
0.73 |
0.65, 0.83 |
< 0.001 |
|
Cardiovascular diseases |
|
|
|
|
|
No |
2,593 (38.3) |
1.00 |
Reference |
|
|
Yes |
18 (26.1) |
0.68 |
0.46, 1.02 |
0.060 |
|
Immunocompromised host* |
|
|
|
|
|
No |
2,608 (38.2) |
1.00 |
Reference |
|
|
Yes |
3 (18.8) |
0.49 |
0.18, 1.36 |
0.172 |
RR, risk ratio; CI, confidence interval
Univariable model estimated by Poisson regression with robust standard error.
† Row percentage
* Immunocompromised hosts include people who have at least one of the following malignancies (solid tumor or hematologic malignancy), diseases that are treated by corticosteroid immune suppressants and chemotherapy.